Clinical Trial Update: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ibrutinib plus rituximab versus FCR in untreated chronic lymphocytic leukemia or small lymphocytic lymphoma; status active not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)
• fludarabine phosphate, cyclophosphamide, and rituximab

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anemia, Chronic Lymphocytic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-08-14